Targeting pediatric diseases with unmet medical needs and zero approved drugs or treatments, Thiogenesis Therapeutics (TTI.v) is a biopharmaceutical company focused on developing novel thiol-based compounds to address mitochondrial dysfunction and its related diseases.
Addressable Market
By focusing on diseases with high unmet medical needs, TTI is targeting a substantial addressable market as mitochondrial diseases collectively affect millions worldwide, with very few effective therapies currently available.
Representing a growing market segment in the pharmaceutical industry, estimates suggest the mitochondrial disease therapies market to be worth USD 1,817 million by 2030
(Source: https://www.rootsanalysis.com/reports/mitochondrial-disease-therapies-market-2019-2030/264.html?utm_source=chatgpt.com)
Lead Compound
TTI's lead compound, TTI-0102, is prodrug with an accelerated regulatory pathway that enhances intracellular cysteine levels. Notably, The compound demonstrated tolerance at significantly higher doses than previously approved cysteamine therapies in clinical studies, with sustained therapeutic levels allowing for potential once-daily dosing.
By leveraging its innovative compounds and focusing on pediatric diseases with no approved therapies, TTI has the potential to make significant strides in addressing critical gaps alongside addressing multiple indications within this growing market, presenting significant commercial and therapeutic opportunities.
For more information, refer to TTI's company overview: https://drive.google.com/file/d/1Obahg9CXnD__6WbReUT93Sgzu6C9EoD_/view
Posted on Behalf of Thiogenesis Therapeutics Corp.